Common Contracts

5 similar Purchase Agreement contracts by Plus Therapeutics, Inc., Genprex, Inc., Tonix Pharmaceuticals Holding Corp., X4 Pharmaceuticals, Inc

PURCHASE AGREEMENT
Purchase Agreement • June 23rd, 2025 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Illinois

THIS PURCHASE AGREEMENT (the "Agreement"), dated as of June 23, 2025, is made by and between X4 PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the "Investor").

PURCHASE AGREEMENT
Purchase Agreement • June 20th, 2025 • Plus Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware

PURCHASE AGREEMENT (the “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined are defined in Section 1 of this Agreement.

PURCHASE AGREEMENT
Purchase Agreement • June 18th, 2025 • Plus Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware

PURCHASE AGREEMENT (the “Agreement”), dated as of June 17, 2025, by and between PLUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined are defined in Section 1 of this Agreement.

PURCHASE AGREEMENT
Purchase Agreement • June 11th, 2025 • Genprex, Inc. • Pharmaceutical preparations • Illinois

PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2025, by and between GENPREX, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).

PURCHASE AGREEMENT
Purchase Agreement • June 11th, 2025 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • Nevada

PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2025, by and between TONIX PHARMACEUTICALS HOLDING CORP., a Nevada corporation (the “Company”), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).